Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    PLoS pathogens · 2024
    AMAyana MoralesSPSanjay PatelMGMarcelo Gabriel HorensteinDADavid A. ScheinbergECEthel Cesarman
    PMID: 38190392PMCID: PMC10898863DOISenior author6 citations
  2. 2
    Molecular cancer research : MCR · 2025
    BBBhavneet BhinderOEOlivier ElementoECEthel Cesarman
    PMID: 39883059PMCID: PMC12048277DOIeCommonsSenior author3 citations
  3. 3
    Blood cancer journal · 2026
    IYIsabella Yingjia KongNGNitya GulatiOEOlivier ElementoAMAri M. Melnick+3 more →ECEthel Cesarman
    PMID: 42020367PMCID: PMC13392450DOISenior author1 citations

Publications

221 publications

Funding

41 grantsView NIH portfolio on RePORTER ↗

Active

12 grants
  • MPI
    Consortium for Advancing Management and Prevention of Cancer in People with HIV - RESOURCE LAB
    National Cancer Institute · 2015–2030 · via EMMES Corporation· 7 renewals
    UM1CA121947-19
  • MPI
    Weill Cornell Initiative for Maximizing Student Development
    National Institute of General Medical Sciences · 2024–2030Training
    T32GM152396-01
  • MPI
    Tri-I Stimulating Access to Research in Residency program (Tri-I StARR - NIAID)
    National Institute of Allergy and Infectious Diseases · 2023–2028
    R38AI174255-01
  • Co-I
    Translating molecular profiles into treatment approaches to target disparities in lymphoma
    Leukemia & Lymphoma Society · 2024–2027 · via Emory University
    LLS 7038-25
  • KP
    Targeting Unmet Needs For B-cell Lymphomas
    Leukemia & Lymphoma Society · 2022–2027
    LLS 7027-23 Project 1
  • MPI
    B cell determinants of EBV latency
    National Cancer Institute · 2022–2027· 2 renewals
    U01CA275301-03S1
  • PI
    Next-Gen Oncopathology Program
    National Cancer Institute · 2022–2027Training
    T32CA260293-05
  • Sub-PI
    Rapid Sample to Answer Diagnosis of Kaposi's Sarcoma Across Sub-Saharan Africa using KS-COMPLETE
    National Cancer Institute · 2022–2027 · via Cornell University - Ithaca
    U01CA269199-04
  • MPI
    Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma
    National Cancer Institute · 2021–2027 · via Northwell Health· 2 renewals
    R01CA260691-04
  • PI
    Project: Next-Gen Oncopathology Program - Charles Ng
    Memorial Sloan Kettering Cancer Center · 2025–2026
    MSKCC 260282-01
  • Co-I
    Epigenetic basis and therapeutic targeting of the unique lymphoma immunological niche
    National Cancer Institute · 2024–2026
    P01CA272295-02
  • PI
    (PQ 6) New Models of KSHV Oncogenesis and KS Immune Environment
    National Cancer Institute · 2020–2026· 2 renewals
    R01CA250074-05
Completed grants (29)
  • PI
    Role of novel onco-histone mutations in B-cell malignancies
    National Cancer Institute · 2019–2025
    R01CA234561-05
  • MPI
    Weill Cornell Initiative for Maximizing Student Development
    National Institute of General Medical Sciences · 2019–2025
    R25GM130494-05
  • KP
    Defining the evolution and tumor microenvironment interactions of classic Hodgkin lymphoma through single-cell multi-omics and genetically engineered mouse models
    Starr Cancer Consortium · 2022–2024
    I15-0016
  • MPI
    Early Stage Diagnosis of Kaposi's Sarcoma in Limited Resource Settings Using KS-Detect
    National Cancer Institute · 2016–2023 · via Cornell University - Ithaca
    UH3CA202723-06
  • KP
    Cohesin complex regulatory proteins and chromosomal architecture in normal and malignant B-cells
    American Society of Hematology Inc · 2022–2023
    ASH 220412-01
  • MPI
    Role Of The Linker Histones H1 In Lymphomas
    American Association for Cancer Research · 2021–2023Fellowship
    AACR 212713-01
  • Co-I
    Modulation Of Viral Latency In EBV+ Lymphomas To Sensitize Tumors To Immunotherapy
    American Society of Hematology Inc · 2021–2023
    ASH 210413-01
  • KP
    Targeting Unmet Clinical Needs for B-Cell Lymphoma
    Leukemia & Lymphoma Society · 2016–2021
    7012-16 CORE A
  • KP
    Rational Translation of EZH2 Targeted Therapy in Germinal Center B-Cell Lymphoma
    National Cancer Institute · 2017–2021Career
    K08CA219473-04
  • PI
    Defining the Cellular Oncogenome of Kaposi Sarcoma
    National Cancer Institute · 2017–2021
    R21CA206851-02
  • Co-I
    Modulation of Viral Latency in EBV-Associated Lymphomas as a Mechanism to Sensitize Tumors to EBV-Directed Cellular Therapy
    Starr Cancer Consortium · 2018–2020
    I11-0043
  • PI
    Nucleoside Analogue Selectively Activated by Adenosine Kinase to Treat ADK-expressing Adenocarcinomas
    Daedalus Fund for Innovation (Weill Cornell) · 2017–2020
    DFI 180572-02
  • PI
    HHV-6 in the Lymphoma Microenvironment
    HHV-6 Foundation · 2019–2020
    HHV 200848-01
  • PI
    Service Agreement: Between WCM (PI Ethel Cesarman) and Fred Hutch (PI Warren Phipps) - Reference Grant: R21 CA206851
    Fred Hutchinson Cancer Research Center · 2017–2020Contract
    SA 183504-03
  • PI
    The 22nd International Conference on Kaposi's sarcoma-associated herpesvirus and Related Agents
    National Cancer Institute · 2019–2020
    R13CA239650-01
  • PI
    Elucidating the Etiologic Role of Linker Histone Mutations in Hematological Malignancy
    Starr Cancer Consortium · 2016–2019
    I9-A9-062
  • Co-I
    Targeting Metabolism in Plasma Cell Neoplasms Using a Nucleoside Analog
    Lymphoma Research Foundation · 2017–2019Fellowship
    LRF 17020210-01
  • MPI
    AIDS Clinical Trials Group (ACTG): A5178: Liver Disease Progression
    National Institute of Allergy and Infectious Diseases · 2013–2018 · via The Brigham & Women's Hospital INC· 2 renewals
    UM1AI068636-12
  • PI
    Modeling KSHV Latency in vivo
    National Cancer Institute · 2012–2018
    R01CA103646-09
  • KP
    Targeting the Hsp90 Oncoproteome in Pediatric Burkitt Lymphoma
    St. Baldrick's Foundation · 2015–2018
    SBF 170821-03
  • PI
    Targeting vFLIP for the Treatment of KSHV-Associated Malignancies
    National Cancer Institute · 2011–2018
    R01CA154228-05 EWOF
  • PI
    Immunology and Microbial Pathogenesis Research Training Program
    National Institute of Allergy and Infectious Diseases · 2010–2016Training
    T32AI007621-15 EW
  • Sub-PI
    Solar-Thermal PCR Assay for the Diagnosis of Kaposi's Sarcoma in Limited Resource Settings
    National Institute of Biomedical Imaging and Bioengineering · 2013–2015 · via Cornell University - Ithaca
    R21EB016803-02
  • MPI
    AIDS Malignancies Clinical Trials Consortium
    National Cancer Institute · 2010–2015 · via EMMES Corporation
    U01CA121947-04
  • Sub-PI
    KS-Detect: A Solar-Powered and Smartphone Integrated Instrument for Point-of-Care Diagnosis of Kaposi's Sarcoma
    National Cancer Institute · 2015–2015 · via A'as, Inc.
    R43CA193096-01
  • MPI
    HIV-Associated Malignancy Research Pilot Projects
    National Cancer Institute · 2010–2014 · via Sloan-Kettering Institute for Cancer Research· 2 renewals
    P30CA008748-47S6
  • PI
    Survival Signals in AIDS Lymphomas
    NCI · 1995–2012 · via NIH RePORTER
    R01CA068939-13
  • PI
    Identifying small molecule inhibitors of KSHV vFLIP-TRAF2 interactions.
    NCI · 2006–2008 · via NIH RePORTER
    R21CA121934-02
  • PI
    KSHV TRANSFORMATION AND ANGIOGENESIS IN KAPOSIS SARCOMA
    NCI · 1999–2003 · via NIH RePORTER
    R01CA082037-03

Honors & distinctions

2 honors
  • Member · American Society for Clinical Investigation · 2001
  • Member · Association of American Physicians

Available technologies

1 technologyView full WCM portfolio ↗

News mentions

7 mentionsView all WCM news ↗
Show 2 more mentions
  • Weill Cornell Medicine Awarded NCI Grant For EBV-Related Lymphoma Research
    February 23, 2023

    Weill Cornell Medicine has been awarded a five-year, $4.2 million grant by the National Cancer Institute, part of the National Institutes of Health, to investigate the molecular mechanisms by which immune cells called B cells interact with Epstein-Barr virus (EBV) to cause lymphoma, particularly in people living with HIV.

  • Inaugural Mastercard Pilot Grant Program Recipients Selected
    April 6, 2022

    Five Weill Cornell Medicine faculty members have been awarded research funding from the Pilot Grant Program of the Mastercard Diversity-Mentorship Collaborative at Weill Cornell Medicine.

Mentoring

5 menteesAll publications with mentees →

External relationships

Professional Services

Fred Hutchinson Cancer Center

Proprietary Interest

Center for Technology Licensing at Cornell University

Other

Genzyme Corporation